Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…NPs [101]. Both studies showed a sustained and enhanced reduction of IOP compared to standard drug solutions.…”

Section: Combination Of Natural and Synthetic Polymersmentioning

confidence: 85%

Advances and limitations of drug delivery systems formulated as eye drops

Jumelle

Gholizadeh

Annabi

et al. 2020

Journal of Controlled Release

224

125

View full text Add to dashboard Cite

show abstract

“…This evidently proved that CS-PEG hydrogel could maintain the effect of rhEPO for a longer time and sustained-release rhEPO effectively. Previous studies of two kinds of hydrogels, used in the treatment of glaucoma, performed that hydrogels could release drugs stably for a long time [12,15] . Our hydrogel was similar to their results in terms of stability.…”

Section: Discussionmentioning

confidence: 99%

“…successfully synthesized thermosensitive PLGA-PEG-PLGA, and indicated that this kind of hydrogel could enhance bioavailability of drugs significantly [14] . The hydrogel we used in present research, which was constructed of chitosan (CS) and polyethylene glycol (PEG), has already been used in the treatment of glaucoma, its sustained IOP lowering effect has been proved [15] . Thus, we highly believed that hydrogel as a drug delivery carrier could maintain the effect of drugs and control the release rate to achieve sustained-release.…”

Section: Introductionmentioning

confidence: 99%

Functional study of early intervention for degenerative retinopathy through hydrogel sustained release system of rhEPO

Zhang

Dai

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Retinitis pigmentosa (RP) is the most common cause of blindness in retinal disease. Long-lasting ocular administration is an effective therapy to delay the progression of RP. And hydrogel sustained release system may be an available and stable drug carrier in the treatment of RP.Method Hydrogel sustained release system was constructed as a drug carrier of recombinant human erythropoietin (rhEPO). We administered retinal degenerative (rd) mice (Pdeb rd1 / Pdeb rd1 ) via subconjunctival or retrobulbar injection at postnatal 2 weeks (PN-2w), examined the mice and tested the factors of retina at two weeks after injection. Electroretinogram (ERG) was used to examine retinal function at PN-4w, western blot and q-PCR were used to test the expression of Bax, Bcl-2, iNOS and VEGFa of retina.Result Photoreceptor apoptosis were alleviated in all rhEPO administrated groups. The retinal blood supply was improved in injection groups. Compared with placebo and blank control groups, rhEPO treatment could enhance the retinal function and delay the progression of disease. Although there was no significant difference between rhEPO hydrogel and rhEPO treated group, photoreceptor apoptosis in rhEPO hydrogel group was less than that in rhEPO group, and the retinal function was better in rhEPO hydrogel group. Moreover, different routes of administration might have little effect on treatment in this research.Conclusion Early intervention can effectively control the progression of the disease. Anti-apoptosis,neuroprotection and erythropoietin of rhEPO could be useful in the treatment of RP. Hydrogel as a long-lasting drug sustained release system was stable and available, and might become a potential drug carrier in the future.

show abstract

“…Evidence demonstrates that resveratrol raises the survival of RGCs [71] and protects the loss of dendrite complexity [72] in glaucoma experimental models. Reports have indicated that resveratrol causes a reduction in IOP in steroid-induced ocular hypertension rats [73] and normal normotensive rabbits [74]. Resveratrol has neuroprotective effects through suppressing apoptosis-related molecule activator protein 1 (AP-1) [75] and elevating neuroprotective factors such as leukemia inhibitory factor (LIF), brain-derived neurotrophic factor (BDNF), oncostatin M (OSM), cardiotrophin 1 (CT-1), and cardiotrophin-like cytokine (CLC) [76] in light-induced retinal degeneration mouse models.…”

Section: Resveratrolmentioning

confidence: 99%

Mitochondrial Dysfunction as a Novel Target for Neuroprotective Nutraceuticals in Ocular Diseases

et al. 2020

View full text Add to dashboard Cite

The eyes require a rich oxygen and nutrient supply; hence, the high-energy demand of the visual system makes it sensitive to oxidative stress. Excessive free radicals result in mitochondrial dysfunction and lead to retinal neurodegeneration, as an early stage of retinal metabolic disorders. Retinal cells are vulnerable because of their coordinated interaction and intricate neural networks. Nutraceuticals are believed to target multiple pathways and have shown neuroprotective benefits by scavenging free radicals and promoting mitochondrial gene expression. Furthermore, encouraging results demonstrate that nutraceuticals improve the organization of retinal cells and visual functions. This review discusses the mitochondrial impairments of retinal cells and the mechanisms underlying the neuroprotective effects of nutraceuticals. However, some unsolved problems still exist between laboratory study and clinical therapy. Poor bioavailability and bioaccessibility strongly limit their development. A new delivery system and improved formulation may offer promise for health care applications.

show abstract

Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction

Cited by 67 publications

References 30 publications

Advances and limitations of drug delivery systems formulated as eye drops

Advances and limitations of drug delivery systems formulated as eye drops

Functional study of early intervention for degenerative retinopathy through hydrogel sustained release system of rhEPO

Mitochondrial Dysfunction as a Novel Target for Neuroprotective Nutraceuticals in Ocular Diseases

Contact Info

Product

Resources

About